File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Clinical implications of angiogenesis in cancers

TitleClinical implications of angiogenesis in cancers
Authors
KeywordsAngiogenesis
Antiangiogenic therapy
Cancer
Prognosis
Issue Date2006
PublisherDove Medical Press Ltd. The Journal's web site is located at http://www.dovepress.com/articles.php?journal_id=2
Citation
Vascular Health And Risk Management, 2006, v. 2 n. 2, p. 97-108 How to Cite?
AbstractAngiogenesis plays an important role in the growth and progression of cancer. The regulation of tumor angiogenesis depends on a net balance of angiogenic factors and antiangiogenic factors, which are secreted by both tumor cells and host-infiltrating cells. Numerous studies have indicated that assessment of angiogenic activity by either microvessel density or expression of angiogenic factors in cancer can provide prognostic information independent of conventional clinicopathological factors such as tumor staging. Some studies also suggested that assessment of tumor angiogenesis may predict cancer response to chemotherapy or radiotherapy. However, the most important clinical implication of tumor angiogenesis is the development of a novel strategy of anticancer therapy targeting tumor vessels instead of cancer cells. Antiangiogenic therapy aims to inhibit the growth of tumor, and current evidence suggests that it works best in combination with conventional cytotoxic chemotherapy. Recently, a monoclonal antibody against vascular endothelial growth factor, which is one of the most potent angiogenic factors, has been approved for clinical use in colorectal cancer patients after a clinical trial confirmed that combining the antibody with standard chemotherapy regimen could prolong patient survival. The clinical implications of angiogenesis in cancer are reviewed in this article. © 2006 Dove Medical Press Limited. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/76664
ISSN
2015 SCImago Journal Rankings: 0.965
References

 

DC FieldValueLanguage
dc.contributor.authorPang, RWCen_HK
dc.contributor.authorPoon, RTPen_HK
dc.date.accessioned2010-09-06T07:23:37Z-
dc.date.available2010-09-06T07:23:37Z-
dc.date.issued2006en_HK
dc.identifier.citationVascular Health And Risk Management, 2006, v. 2 n. 2, p. 97-108en_HK
dc.identifier.issn1176-6344en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76664-
dc.description.abstractAngiogenesis plays an important role in the growth and progression of cancer. The regulation of tumor angiogenesis depends on a net balance of angiogenic factors and antiangiogenic factors, which are secreted by both tumor cells and host-infiltrating cells. Numerous studies have indicated that assessment of angiogenic activity by either microvessel density or expression of angiogenic factors in cancer can provide prognostic information independent of conventional clinicopathological factors such as tumor staging. Some studies also suggested that assessment of tumor angiogenesis may predict cancer response to chemotherapy or radiotherapy. However, the most important clinical implication of tumor angiogenesis is the development of a novel strategy of anticancer therapy targeting tumor vessels instead of cancer cells. Antiangiogenic therapy aims to inhibit the growth of tumor, and current evidence suggests that it works best in combination with conventional cytotoxic chemotherapy. Recently, a monoclonal antibody against vascular endothelial growth factor, which is one of the most potent angiogenic factors, has been approved for clinical use in colorectal cancer patients after a clinical trial confirmed that combining the antibody with standard chemotherapy regimen could prolong patient survival. The clinical implications of angiogenesis in cancer are reviewed in this article. © 2006 Dove Medical Press Limited. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherDove Medical Press Ltd. The Journal's web site is located at http://www.dovepress.com/articles.php?journal_id=2en_HK
dc.relation.ispartofVascular Health and Risk Managementen_HK
dc.subjectAngiogenesisen_HK
dc.subjectAntiangiogenic therapyen_HK
dc.subjectCanceren_HK
dc.subjectPrognosisen_HK
dc.titleClinical implications of angiogenesis in cancersen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1176-6344&volume=2&issue=2&spage=97&epage=108&date=2006&atitle=Clinical+implications+of+angiogenesis+in+cancersen_HK
dc.identifier.emailPang, RWC: robertap@hkucc.hku.hken_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.authorityPang, RWC=rp00274en_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2147/vhrm.2006.2.2.97en_HK
dc.identifier.pmid17319453-
dc.identifier.scopuseid_2-s2.0-33744962527en_HK
dc.identifier.hkuros118524en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33744962527&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume2en_HK
dc.identifier.issue2en_HK
dc.identifier.spage97en_HK
dc.identifier.epage108en_HK
dc.publisher.placeNew Zealanden_HK
dc.identifier.scopusauthoridPang, RWC=7004376659en_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats